Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CPT2 | P23786 | 4/20 | 0.47 |
| ▸ | CPT1A | P50416 | 4/20 | 0.47 |
| ▸ | CPT1B | Q92523 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088413 | 0.94 | MEN1 (0.49) | L3MBTL1NLRP3GPR119MAPTCPT2 | |
| SCHEMBL3089841 | 0.91 | KMT2A (0.55) | L3MBTL1MAPTCPT2CPT1ACPT1B | |
| SCHEMBL3082495 | 0.86 | KMT2A (0.50) | L3MBTL1MAPTCPT2CPT1ACPT1B | |
| SCHEMBL15062792 | 0.83 | L3MBTL1 (0.51) | L3MBTL1NLRP3GPR119MAPTCPT2 | |
| SCHEMBL3091055 | 0.82 | L3MBTL1 (0.48) | L3MBTL1NLRP3MAPTCPT2CPT1A | |
| SCHEMBL3088253 | 0.81 | CPT1A (0.55) | L3MBTL1NLRP3CPT2CPT1ACPT1B | |
| SCHEMBL2898003 | 0.79 | CPT1A (0.68) | MAPTCPT2CPT1ACPT1BKMT2A | |
| SCHEMBL13495471 | 0.78 | GPR119 (0.60) | L3MBTL1GPR119MAPTKMT2ACYP2C9 | |
| SCHEMBL3079208 | 0.77 | AKR1C3 (0.52) | L3MBTL1KMT2ACYP2C9MEN1POLB | |
| SCHEMBL3077739 | 0.77 | CYP3A4 (0.58) | L3MBTL1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393812-B1 | SUBSTITUTED SPIROAMIDES AS B1R-MODULATORS | GRUENENTHAL GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234340-A1 | Substituted Spiroamide Compounds | BDKRB1, BDKRB2, AVPR1B | L3MBTL1 4344/4885NLRP3 301/4885GPR119 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.